YBX1 and myeloproliferative disorder: The genetic absence of YBX1 in an MPN mouse model driven by JAK2-V617F prevented disease formation and importantly, also allowed for ruxolitinib treatment to lead to molecular remission, which was not seen when YBX1 was present.